Phase 1Recruiting
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
A Phase 1, First-in-Human Study of MEN2501, a KIF18A Inhibitor, as Monotherapy in Participants With Platinum-Resistant Ovarian Cancer
- Sponsor
- Stemline Therapeutics, Inc. (Industry)
- Enrolment
- 100 planned
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- MEN2501
- Ages
- adults, older adults
- Registry
- NCT07226427
Full record on ClinicalTrials.gov
From the registry
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Primary outcomes
- Part A Only: Number of Participants with Dose-limiting Toxicities (DLTs)
- Part B Only: Recommended Phase 2 Dose (RP2D) of MEN2501
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered